Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26%
Sunharbo (asundexian) is the first FDA-approved factor XIa inhibitor for secondary stroke prevention, but key limitations and risks do remain.
FOX News
Full text, translation and AI summary — after signing in
- The full article in your language
- AI summary and translation from the original
- The same account works in the Suviy app
Comments
Sign in to join the conversation. Sign in
No comments yet.